4. Caley CF, Weber SS. Sulpiride: an antipsychotic with selective dopaminergic antagonist properties. Ann Pharmacother.,1995, 2, 29, 152–160
5. Wilson JM, Sanyal S, Van Tol H. Dopamine D2 and D4 receptor ligands: relation to antipsychotic action. Eur. J. Pharmacol., 1998, 351, 3, 273–286
6. Emilien G, Maloteaux JM, Geurts M et al. Dopamine receptors – physiological understanding to therapeutic intervention. Pharmacol and Therapeutics, 1999, 84, 2, 133–156
7. Herrera–Marschitz M, Stahle L, Tossman U et al. Behavioural and biochemical studies with the benzamide sulpiride in rats. Acta Psychiatr. Scand. Suppl, 1984, 311, 147–162
8. Barrett RJ, Ginos JZ, Lokhandwala MF, Evaluation of peripheral dopamine receptor and alpha–adrenoceptor blocking activity of sulpiride. Eur. J. Pharmacol.,1982, 4, 79, 273–281
9. Mauri MC, Bravin S, Bitetto A et al. A risk–benefit assessment of sulpiride in the treatment of schizophrenia. Drug Saf., 1996, 5, 14, 288–298
10. Soares BG, Fenton M, Chue P. Sulpiride for schizophrenia. Cohrane Database Syst.Rev., 2000, Issue 2
11. Munk–Andersen E, Behnke K, Heltberg J et al. Sulpiride versus haloperidol, a clinical trial in achizophrenia. A preliminary report. Acta Psychiatr. Scand. Suppl., 1984, 311, 31–41
12. Shiloh R, Zemishlany Z, Aizenberg D et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double–blind, placebo–controlled study. Br.J.Psychiatry,1997,12, 171, 569–573
13. Raskin S, Durst R, Katz G et al. Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment–resistant achizophrenia. J.Clin.Psychopharmacol.,2000, 20, 500–503
14. Harnryd C, Bjerkenstedt L, Bjork K, et al. Clinical evaluation of sulpiride in schizophrenic patients – a double–blind comparison with chlorpromazine. Acta Psychiiatr. Scand. Suppl.,1984, 311, 7–30
15. Jenner P, Marsden CD. The mode of action of sulpiride as an atypical antidepressant agent. Adv. Biochem. Psychopharmacol.,1982, 32, 85–103
16. Barfai A, Wiesel FA. Effect of sulpiride on vigilance in healthy subjects. Int.J.Psychophysiol., 1986, 4, 1–5
17. Meier–Lindenberg A, Rammsayer T, Ulferts J et al. The effect of sulpiride on psychomotor performance and subjective tolerance. Eur. Neuropsychopharmacol.,1997, 7, 219–223
18. Rao VA, Bailey J, Bishop M et al., A clinical and pharmacodynamic evaluation of sulpiride. Psychopharmacology,1981, 73, 77–80
19. McMurdo ME, Hovie PW, Lewis M et al. Prolactin response to low dose sulpiride. Br.J. Clin. Pharmacol., 1987, 8, 24, 133–137
20. Buvat J, Racadot A, Buvat–Herbaut M. Basal prolactinaemia and responses to TRH and to sulpiride in different categories of male sexual dysfunctions. Acta Psychiatr. Belg.,1997, 80, 487–493
21. Ylikorkala O, Kauppila A, Kivinen S et al. Sulpiride improves inadequate lactation. Br. Med. J., 1982, 7, 285, 249–251
22. Aono T, Aki T, Koike K et al. Effect of sulpiride on poor puerperal lactation. Am.J. Obstet. Gynecol.,1982, 8, 143, 927–932
23. Ylikorkala O, Kauppila A, Kivinen S et al. Treatment of inadequate lactation with iral sulpiride and buccal oxytocin. Obstet. Gynecol, 1984, 1, 63, 57–60
24. Verbeeck WJ, Berk M, Paiker J et al. The prolactin response to sulpiride in major depression: the role of the D(2) receptor in depression. Eur. Neuropsychopharmacol., 2001, 6, 11, 215–220
25. Vacceri A, Dall’Olio R, Gaggi R, et al. Antidepressant versus neuroleptic activities of sulpiride isomers on four animal models of depression. Psychopharmacology (Berl),1984, 83, 28–33
26. Benkert O, Holsboer F. Effect of sulpiride in endogenous depression. Acta Psychiatr. Scand. Suppl, 1984, 311, 43–48
27. Maier W, Benkert O, Treatment of chronic depression with sulpiride: evidence of efficacy in placebo–controlled single case studies. Psychopharmacology (Berl),1994, 8, 115, 495–501
28. Lestynek JL. Sulpiride and depression. Sem. Hop., 1983, 59, 2354–2357
29. Ruter E, Degner D, Munzel U. Antidepressant action of sulpiride. Results of a placebo–controlled double–blind trial. Pharmacopsychiatry,1999, 32,127–135
30. Meyers C, Vranckx C, Elgen K. Psychosomatic disorders in general practice: comparisons of treatment with flupentixol, diazepam and sulpiride. Pharmacotherapeutica,1985, 4, 244–250
31. Altamura AC, Mauri MC, Regazzetti G. L–sulpiride in the treatment of somatoform disturbances: a double–blind study with racemic sulpiride. Minerva Psichiatr.,2000, 32, 25–29
32. Cavazzutti E, Bertlini A, Vergoni AV et al. L–Sulpiride at a low, non–neuroleptic dose, prevents conditioned fear stress–induced fresing behavior in rats. Psychopharmacology (Berl),1999, 3, 143, 20–23
33. Ferreri M, Florent C, Gerard D, Sulpiride: study of 669 patient presenting with pain psychological origin. Encephale, 2000, 26, 58–66
34. Drago F, Arezzi A, Virzi A. Effects of acute or chronic administration of substituted benzamides in experimental models of depression in rats. Eur. Neuropsychopharmacology, 2000, 10, 437–442
35. WHO Guide to Mental Health in Primary Care. London: Royal Society of Medicine Press, 2000
36. Schultz W. Dopamine neurons and their role in reward mechanisms. Current Opinion in Neurobiology, 1997, 7, 191–197
37. Spanagel R., Weiss F. The dopamine hypothesis of reward: past and current status. Trnds in Neurosciences,1999, 22, 521–527
38. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning or ince salience? Brain Res.Rev,1998, 28, 3, 309–369
39. Vergoni AV, Forgione A, Bertolini A. Chronic administration of I–sulpiride at non–neuroleptic doses reduces the duration of immobility in experimental models of «depression–like» behavior. Psychopharmacology (Berl),1995, 121, 279–281
40. Mizuki Y. Suetsugi M, Ushijima I et al. Differential effects of dopaminergic drugs on anxiety and arousal in healthy volunteers with high and low anxiety. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1997, 21, 573–590
41. Guslandi M. Antiemetic properties of levo–sulpiride. Minerva Med.,1990, 12, 81, 855–860
42. Caldara R, Masci E, Cambielli M et al. Effect of sulpiride isomers on gastric acid and gastrin secretion in healthy man. Eur.J.Clin.Pharmacol.,1983, 25, 319–322
43. Cohen N, Alon I, Almoznino–Sarfian D et al. Sulpiride versus metoclopramide in nononcologic patiets with vomiting and nausea. J.Clin. Gastroenterol.1999, 7, 29, 59–62
44. Corazza GR, Biagi F, Albano O et al. Levosulpiride in functional dyspepsia: a multicentric, double–blind, controlled trial. Ital. J. Gastroenterol.,2000, 28, 317–323
45. Mansi C, Savarino V, Vigneri S et al. Gastrocinetic effects of levosulpiride in dyspeptic patients with diabetic gastroparesis. Am.J. Gastroenterol., 1995, 11, 90, 1989–1993
46. Mansi C, Savarino V, Vigneri S et al. Effect of D2–dopamine raceptor antagonist levosulpiride on diabetic cholecystoparesis: a double–blind crossover study. Aliment. Pharmacol. Ther.,1995, 4, 9, 185–189
47. Szabelska K, Chojnacki J, Grzegorczyk J et al. Effect of procinetic drugs inhibiting dopaminergic system on gallbladder motility in subjects with duodenal ulcer. Pol. Merkuriusz. Lek., 1999, 6, 188–191
48. Pich EM, Samanin R., Disinhibitory effects of buspirone and low doses of sulpiride and haloperidol in two experimental anxiety models in rats: possible role of dopamine. Psychopharmacology (Berl), 1986, 89, 125–130